Small molecule lead discovery company Nuevolution has partnered with Duke University, the Howard Hughes Medical Institute and Lexicon Pharmaceuticals, to evaluate the biological mechanism of action of a specified GPCR drug target.
The scientific collaboration will leverage Nuevolution’s proprietary Chemetics technology for small molecule drug discovery.
Both Nuevolution and Lexicon will provide access to selected chemical libraries created using the Chemetics technology.
Nuevolution chief scientific officer Thomas Franch said under the scientific collaboration the company looks forward to working with the scientific group of Dr Lefkowitz and its partner Lexicon Pharmaceuticals.
Under the collaboration, several diverse small molecules will be screened in an attempt to discover compounds with certain novel and unique properties against the GPCR drug target.
If successful, the project could provide a new level of understanding on the mechanism of action of GPCRs, according to Nuevolution.
Lexicon executive vice-president and chief scientific officer Dr Brian Zambrowicz said the Chemetics technology was successfully used to identify novel chemotypes for internal programs.
The company will now explore the use of its DNA-tagged libraries of diverse chemical compounds in the screening of GPCRs, according to Zambrowicz.
"We look forward to working with Nuevolution and Dr. Lefkowitz’s team at Duke University on this project," Zambrowicz said.